title: Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
abstract: BACKGROUND
  Optimal adherence to imatinib therapy is of paramount importance to maximise treatment effectiveness in patients with chronic myeloid leukaemia (CML). The main objective of this study was to investigate patient-reported personal factors associated with adherence behaviour.
  
  
  METHODS
  Analysis was conducted on 413 CML patients receiving long-term therapy with imatinib. Adherence behaviour was measured with the Morisky Medication Adherence Scale and personal factors investigated included: quality of life, perceived social support, fatigue, symptom burden, psychological wellbeing and desire for additional information. Key socio-demographic and treatment-related factors were also taken into account. Univariate and multivariate logistic regression analyses were used to investigate factors associated with optimal adherence to therapy.
  
  
  RESULTS
  In all, 53% of patients reported an optimal adherence behaviour. The final multivariate model retained the following variables as independent predictors of optimal adherence to therapy: desire for more information (ref. no), odds ratio (OR)=0.43 (95% confidence interval (CI), 0.29-0.66; P<0.001), social support (higher score representing greater support), OR=1.29 (95% CI, 1.11-1.49; P<0.001) and concomitant drug burden (ref. no), OR=1.82 (95% CI, 1.18-2.80; P=0.006).
  
  
  CONCLUSIONS
  This study suggests that a higher level of social support, satisfaction with information received and concomitant drug burden are the main factors associated with greater adherence to long-term imatinib therapy.
authors.affiliation: Italian Group for Adult Hematologic Diseases, Data Center and Health Outcomes Research Unit, Via Benevento, 6, 00161 Rome, Italy. f.efficace@gimema.it
authors.forename: F
authors.initials: F
authors.lastname: Efficace
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: F
authors.initials: F
authors.lastname: Cottone
authors.forename: F
authors.initials: F
authors.lastname: Castagnetti
authors.forename: M
authors.initials: M
authors.lastname: Breccia
authors.forename: G
authors.initials: G
authors.lastname: Alimena
authors.forename: A
authors.initials: A
authors.lastname: Iurlo
authors.forename: A R
authors.initials: AR
authors.lastname: Rossi
authors.forename: S
authors.initials: S
authors.lastname: Pardini
authors.forename: F
authors.initials: F
authors.lastname: Gherlinzoni
authors.forename: M
authors.initials: M
authors.lastname: Salvucci
authors.forename: M
authors.initials: M
authors.lastname: Tiribelli
authors.forename: M
authors.initials: M
authors.lastname: Vignetti
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D005221:Fatigue / Q000209:etiology / Q000523:psychology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D057226:Information Seeking Behavior; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D016015:Logistic Models; D008297:Male; D055118:Medication Adherence / Q000523:psychology; D008875:Middle Aged; D016017:Odds Ratio; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D012307:Risk Factors; D012944:Social Support; D016896:Treatment Outcome; D016903:Drug Monitoring
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate